Share ownership BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 06:15:15 10/03/2026 pm IST			5-day change	1st Jan Change
318.30 ^SEK	+6.24%		+9.45%	+2.12%

20/02	Nordea Raises Price Target for Bioarctic to 240 Kronor (236), Reiterates Sell	FW
19/02	Lannebo Health and New Technology Down 5.1 Percent in January — Bico and Raysearch Weigh on Performance	FW

Share class: BioArctic AB

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	1,43,99,996	0	0	44.08 %
Stock B	1	7,39,89,039	3,89,58,857 ( 52.65 %)	0

Major shareholders: BioArctic AB

Name	Equities	%	Valuation
Lars Gunnar Lannfelt 26.28 %	1,95,11,302	26.28 %	703 M kr
Pär Lars Gellerfors 16.12 %	1,19,69,451	16.12 %	431 M kr
Fjärde AP-fonden 7.298 %	54,18,493	7.298 %	195 M kr
Swedbank Robur Fonder AB 4.218 %	31,31,849	4.218 %	113 M kr
RA Capital Management LP 4.199 %	31,17,736	4.199 %	112 M kr
Nordea Investment Management AB 3.779 %	28,05,743	3.779 %	101 M kr
Unionen 3.367 %	25,00,000	3.367 %	90 M kr
Tredje AP-fonden 1.609 %	11,94,212	1.609 %	43 M kr
Indecap Fonder AB 0.6975 %	5,17,858	0.6975 %	19 M kr
Storebrand Asset Management AS 0.4509 %	3,34,784	0.4509 %	12 M kr
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Lars Gunnar Lannfelt 60 %	86,39,998	60 %	311 M kr
Pär Lars Gellerfors 40 %	57,59,998	40 %	208 M kr

Breakdown by shareholder type

Individuals	62.13%
Institutional	22.64%
Other	3.37%
Unknown	11.86%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	62.15%
Sweden	21.19%
United States	4.2%
Norway	0.45%
Netherlands	0.08%
Finland	0.06%
Australia	0.01%

Based on 1000 largest holdings

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Employees

131

Sector

Biotechnology & Medical Research

Calendar

20/05 - Earnings release - Q1 2026

More about the company